Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Buy to Neutral. Analyst Price Forecast Suggests 14.00% Downside As of December 23, 2024, ...

As of December 3, 2024, the average one-year price target for Inari Medical is $66.15/share ... deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by the ...

Stryker's acquisition of Inari for $4.9B enhances its neurovascular ... has not really been a player in venous markets like pulmonary embolism (or PE), deep vein thrombosis (or DVT), limb ischemia ...

Charles R. Goulding and Preeti Sulibhavi examine how Stryker's acquisition of Inari Medical is set to transform vascular care ...

Large-bore mechanical thrombectomy scored a win over catheter-directed thrombolysis in patients with acute intermediate-risk pulmonary embolism. In the PEERLESS ... those treated with the FlowTriever ...